Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Tumor Treating Fields in Neuro-Oncological Practice.

Mrugala MM, Ruzevick J, Zlomanczuk P, Lukas RV.

Curr Oncol Rep. 2017 Aug;19(8):53. doi: 10.1007/s11912-017-0611-8. Review.

PMID:
28664468
2.

Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.

Zhu P, Zhu JJ.

Chin Clin Oncol. 2017 Aug;6(4):41. doi: 10.21037/cco.2017.06.29. Review.

3.

The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.

Turner SG, Gergel T, Wu H, Lacroix M, Toms SA.

World J Surg Oncol. 2014 May 22;12:162. doi: 10.1186/1477-7819-12-162.

4.

Response patterns of recurrent glioblastomas treated with tumor-treating fields.

Vymazal J, Wong ET.

Semin Oncol. 2014 Oct;41 Suppl 6:S14-24. doi: 10.1053/j.seminoncol.2014.09.009. Epub 2014 Sep 16. Erratum in: Semin Oncol. 2015 Jun;42(3):e44-55.

5.

NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbalý V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH.

Eur J Cancer. 2012 Sep;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub 2012 May 18.

6.

Case of glioblastoma patient treated with tumor treating fields therapy at recurrence degenerating to sarcoma.

Majd P, O'Connell DE, Kim RC, Bota DA, Carrillo JA.

CNS Oncol. 2017 Apr;6(2):89-94. doi: 10.2217/cns-2016-0035. Epub 2017 Mar 17.

7.

Tumor treating fields therapy device for glioblastoma: physics and clinical practice considerations.

Lok E, Swanson KD, Wong ET.

Expert Rev Med Devices. 2015;12(6):717-26. doi: 10.1586/17434440.2015.1086641. Epub 2015 Oct 29. Review.

PMID:
26513694
8.

The effects of alternating electric fields in glioblastoma: current evidence on therapeutic mechanisms and clinical outcomes.

Rehman AA, Elmore KB, Mattei TA.

Neurosurg Focus. 2015 Mar;38(3):E14. doi: 10.3171/2015.1.FOCUS14742. Review.

PMID:
25727223
9.

Tumor treating fields: a novel treatment modality and its use in brain tumors.

Hottinger AF, Pacheco P, Stupp R.

Neuro Oncol. 2016 Oct;18(10):1338-49. doi: 10.1093/neuonc/now182. Review.

10.
11.

Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).

Mrugala MM, Engelhard HH, Dinh Tran D, Kew Y, Cavaliere R, Villano JL, Annenelie Bota D, Rudnick J, Love Sumrall A, Zhu JJ, Butowski N.

Semin Oncol. 2014 Oct;41 Suppl 6:S4-S13. doi: 10.1053/j.seminoncol.2014.09.010. Epub 2014 Sep 16. Erratum in: Semin Oncol. 2015 Jun;42(3):e33-43.

12.

Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy.

Saria MG, Kesari S.

Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S9-S13. doi: 10.1188/16.CJON.S1.9-13. Review.

13.

Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation.

Kim EH, Kim YH, Song HS, Jeong YK, Lee JY, Sung J, Yoo SH, Yoon M.

Oncotarget. 2016 Sep 20;7(38):62267-62279. doi: 10.18632/oncotarget.11407.

14.

Delayed response and survival from NovoTTF-100A in recurrent GBM.

Villano JL, Williams LE, Watson KS, Ignatius N, Wilson MT, Valyi-Nagy T, Michals EA, Engelhard HH.

Med Oncol. 2013 Mar;30(1):338. doi: 10.1007/s12032-012-0338-1. Epub 2013 Jan 10.

PMID:
23307238
15.

Tumor-Treating Fields: Nursing Implications for an Emerging Technology
.

Chang A.

Clin J Oncol Nurs. 2017 Jun 1;21(3):302-304. doi: 10.1188/17.CJON.302-304.

PMID:
28524900
16.
17.

Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.

Lacouture ME, Davis ME, Elzinga G, Butowski N, Tran D, Villano JL, DiMeglio L, Davies AM, Wong ET.

Semin Oncol. 2014 Jun;41 Suppl 4:S1-14. doi: 10.1053/j.seminoncol.2014.03.011. Epub 2014 Mar 19.

18.

NovoTTF-100A: a new treatment modality for recurrent glioblastoma.

Fonkem E, Wong ET.

Expert Rev Neurother. 2012 Aug;12(8):895-9. Epub 2012 Jun 19. Review.

PMID:
22708931
19.

A roundtable discussion on the clinical challenges and options for the treatment of glioblastoma: introducing a novel modality, TTFields.

Butowski N, Wong ET, Mehta MP, Wilson LK.

Semin Oncol. 2013 Dec;40(6):S2-4. doi: 10.1053/j.seminoncol.2013.10.002. Epub 2013 Oct 10.

PMID:
24331200
20.

Skin toxicities associated with tumor treating fields: case based review.

Lukas RV, Ratermann KL, Wong ET, Villano JL.

J Neurooncol. 2017 Dec;135(3):593-599. doi: 10.1007/s11060-017-2612-8. Epub 2017 Aug 28.

PMID:
28849343

Supplemental Content

Support Center